[The role of antioxidants in the complex treatment of patients with chronic prostatitis]

Prostatitis is considered to be the most common disease in men. A wide range of drugs used for the treatment of patients with chronic prostatitis (CP) does not always result in the cure. Since the role of free radicals in the pathogenesis of chronic inflammation has been studied extensively, antioxidant therapy in CP is very promising.

To evaluate the efficiency of the dietary supplement "Querceprost" in the combined treatment of patients with CP of II and IIIA categories.

A total of 120 patients with average age of 35.6 years and a verified diagnosis of "CP of II or IIIA categories" were included in the study. All patients were divided into two main groups, depending on the presence of chronic bacterial (n=30) or chronic abacterial prostatitis (n=30) and two control groups with a similar diagnosis (30 men in each). In the main groups, standard therapy was accompanied by taking the dietary supplement "Querceprost" 2 capsules per day during meals for 1 month. In the control groups, patients received only standard therapy depending on the category of CP. The results were assessed after 1 and 3 months from the start of treatment. During the study, medical history was taken and physical examination was performed. In addition, IPSS (International Prostate Symptom Score), Lower Urinary Tract Symptoms (LUTS), IIEF-15 (International Index of Erectile Function), and NIH-CPSI scales were filled out. Clinical and biochemical laboratory tests of blood and urine, measurement of serum prostate-specific antigen (PSA) level, as well as microscopic examination of the expressed prostatic secretions were done. All patients underwent uroflowmetry, ultrasound examination (US) of the bladder with determination of the postvoid residual and transrectal US of the prostate.

The use of antioxidant complex "Querceprost" in the combination therapy of CP (category II and IIIA) in men of resulted in the decrease in the pain severity score and improvement of the patient's impression of his condition according to the NIH-CPSI. The total IPSS score significantly decreased compared to baseline values, and it was between mild and moderate symptoms, while the positive dynamics persisted even after 3 months from the start of therapy. The resolution of the inflammatory process was proved by a decrease in the number of leukocytes in the expressed prostatic secretions after the use of antioxidants. Also, in those patients, who took antioxidant as part of the combined therapy, an improvement in the erectile function according to the IIEF-15 scale and an increase in the urine flow rate on uroflowmetry were noted.

The use of antioxidants from the dietary supplement "Querceprost" in the combined therapy of CP (category II and IIIA) is not only accompanied by a significant reduction or resolution of symptoms, but also allows to achieve consistent effect.